Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Optimized HF therapy in patients with advanced cancer in palliative care: dosing strategies from the EMPATICC trial

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB
[thumbnail of Appendix]
Preview
PDF (Appendix) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
46kB

Item Type:Article
Title:Optimized HF therapy in patients with advanced cancer in palliative care: dosing strategies from the EMPATICC trial
Creators Name:Anker, Markus S., Shahzeb Khan, Muhammad, Mahabadi, Amir A., Totzeck, Matthias, Tewes, Mitra, Arshad, Muhammad Sameer, Mincu, Raluca, Butler, Javed, Keller, Ulrich, Ahn, Johann, Bullinger, Lars, Modest, Dominik P., Landmesser, Ulf, Lehmann, Lorenz H., Bercker, Sven, Laufs, Ulrich, Böhm, Michael, Merkely, Bela, Diek, Monika, Heise, Tim, Hellmich, Martin, Placzek, Marius, Friede, Tim, Anker, Stefan D. and Rassaf, Tienush
Abstract:Cardiac wasting occurs in patients with end­stage cancer, leading to the development of heart failure (HF)­like symptoms char­acterized by dyspnea, reduced physical function, and diminished quality of life. EMPATICC (EMPower the heArt of patients with TermInal Cancer using Cardiac medicines) is a randomized controlled trial designed to evaluate the impact of optimized HF therapy in patients with advanced cancer receiving specialized palliative care. Given the susceptibility to adverse drug events in this vulnerable population, the trial employed a protocol­driven approach for the initiation and titration of each medication.EMPATICC is a multi­center, randomized, double­blind, controlled, proof­of­concept trial that enrolled 93 patients with stage IV solid tumors (per Union for International Cancer Control [UICC]), under palliative care, with clinical features in­dicating cardiovascular risk and functional limitation. Participants were randomized 1:1 to receive optimized HF therapy, in­cluding sacubitril/valsartan, empagliflozin, ivabradine, and ferric carboxymaltose (FCM), or 1­4 placebo therapies on top of usual care. All trial medications (or placebo) that was available in tablet form were provided in pre­packed containers to support blinding. Blue placebo tablets were used for empagliflozin, white tablets for sacubitril/valsartan, and pink tablets for ivabradine. Blinded staff members did not have access to individual tablet packaging or knowledge of color allocations. Addi­tionally, the meaning of the color­coded tablets was not disclosed to the blind staff members throughout the trial. Dosing protocols were guided by predefined criteria, including blood pressure, renal function, heart rate, hemoglobin, and body weight, and they were implemented by unblinded staff. Algorithms accounted for prior RAAS inhibitor exposure when initiating sacubitril/valsartan; ensured hemodynamic stability and sinus rhythm for ivabradine; assessed renal reserve when starting empagliflozin to support safe and effective titration; and accounted for body weight and hemoglobin levels when initiating FCM. To ensure consistent implementation across five centers in Germany, visual flowcharts were designed.The EMPATICC trial provides a practical, protocol­driven approach for delivering HF therapy in the palliative oncology setting. Dosing algo­rithms outlined in this study could serve as a model for structured cardiovascular care in patients with advanced cancer.
Keywords:Heart Failure Therapy, End Stage Cancer, Cardiac Wasting, Clinical Trial
Source:Global Cardiology
ISSN:2975-2728
Publisher:PAGE Press
Page Range:3-9
Date:20 August 2025
Official Publication:https://doi.org/10.4081/cardio.2025.78

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library